{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T18:28:36Z","timestamp":1778783316518,"version":"3.51.4"},"reference-count":41,"publisher":"Informa UK Limited","issue":"18","license":[{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Pfizer Inc. No grant number is applicable"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2019,6,30]]},"DOI":"10.2217\/fon-2018-0858","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T07:22:34Z","timestamp":1556004154000},"page":"2175-2190","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Safety and Effectiveness of Classical and Alternative Sunitinib Dosing Schedules For Metastatic Renal Cell Carcinoma: A Meta-Analysis"],"prefix":"10.1080","volume":"15","author":[{"given":"Seye","family":"Abogunrin","sequence":"first","affiliation":[{"name":"Meta Research, Evidera, London, W6 8BJ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajibade O","family":"Ashaye","sequence":"additional","affiliation":[{"name":"Formerly Meta Research, Evidera, Waltham, MA 02451, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph C","family":"Cappelleri","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, CT 06340, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew G","family":"Clair","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., New York, NY 10017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Fahrbach","sequence":"additional","affiliation":[{"name":"Meta Research, Evidera, Waltham, MA 02451, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishnan","family":"Ramaswamy","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., New York, NY 10017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucile","family":"Serfass","sequence":"additional","affiliation":[{"name":"Pfizer Oncology, 75668Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy","family":"Srinivas","sequence":"additional","affiliation":[{"name":"Stanford University Medical Center, Stanford, CA94304, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Despina","family":"Thomaidou","sequence":"additional","affiliation":[{"name":"Pfizer, 15451\u00a0Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Zanotti","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., New York, NY 10017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,4,23]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.06.049"},{"key":"e_1_3_5_3_1","unstructured":"Ferlay J ShinHR BrayF FormanD MathersC ParkinDM. GLOBOCAN Cancer Incidence and Mortality Worldwide. 2012; http:\/\/globocan.iarc.fr."},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2007.12.001"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.06.032"},{"issue":"2","key":"e_1_3_5_6_1","first-page":"339","article-title":"Current management options in metastatic renal cell cancer","volume":"11","author":"Gangadaran SGD","year":"2017","unstructured":"Gangadaran SGD . Current management options in metastatic renal cell cancer. Oncol. Rev.11(2), 339 (2017).","journal-title":"Oncol. Rev."},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1985"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"e_1_3_5_10_1","unstructured":"Ono Pharmaceutical Bristol-Myers Squibb . Bristol-Myers Squibb receives FDA approval for opdivo (nivolumab) in previously treated locally advanced or metastatic urothelial carcinoma a type of bladder cancer. 2017 14."},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1293"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065044"},{"key":"e_1_3_5_13_1","doi-asserted-by":"crossref","unstructured":"Escudier B Gr\u00c3\u00bcnwaldV GillessenSet al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis treatment and follow-up. 2019.","DOI":"10.1093\/annonc\/mdz056"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.196"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303989"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-014-9889-0"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1170-y"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.08.090"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26440"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-017-0209-5"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12849"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2005.12.001"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7521.897"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1875"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv357"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2012.03204.x"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv315"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyt232"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.01.025"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2015.03.008"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-015-0528-8"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.4_suppl.417"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2016.10.010"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.01.016"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwm324"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2014.07.006"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.7398"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.1485"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq204"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-2613-8"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2018-0858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:44Z","timestamp":1719125144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2018-0858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,23]]},"references-count":41,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2019,6,30]]}},"alternative-id":["10.2217\/fon-2018-0858"],"URL":"https:\/\/doi.org\/10.2217\/fon-2018-0858","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}